Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data
Graphical abstract
Introduction
Current treatment for children with primary central nervous system (CNS) tumors includes surgery, radiation, and chemotherapy. With this approach to therapy, the 5-year survival rate is 72.5%, but the cure rate is only 50% (Nageswara Rao et al., 2012). Even with new diagnostic tools and technologies, survival rates for certain CNS tumors have not increased significantly over the last twenty years (Pollack, 2011). Often, treatment of these tumors results in severe acute and long-term neurological and endocrine impairments that manifest later in life. Together, poor cure rates and adverse outcomes clearly highlight the need for innovative approaches in anticancer drug development for pediatric CNS tumors.
However, development of safe and effective anticancer drugs for children with CNS tumors is especially difficult for several reasons. One of the more challenging aspects is accruing sufficient numbers of patients for rapid evaluation of novel therapies in early phase clinical trials. Although pediatric CNS tumors are the most common cause of cancer-related deaths in children, they only account for 25% of all childhood cancers (Paul et al., 2013), and clinical trials are complicated by the heterogeneity of many CNS malignancies (Taylor et al., 2012). Pediatric CNS tumors are traditionally classified and graded by location and histology according to World Health Organization (WHO) guidelines and can be further stratified into molecular subgroups using gene expression profiling (Robinson et al. 2012). Many anticancer drugs are not necessarily efficacious in all subtypes of a tumor. Moreover, they may have non-specific mechanisms and often cause a variety of off-target side effects. Thus, an urgent need exists for the rapid evaluation of alternative, subgroup-specific therapies that can be investigated in preclinical studies with the use of molecularly relevant animal models of these subgroups.
Another significant challenge in treating CNS malignancies is reaching therapeutic drug exposures at the target site. Attaining adequate drug concentrations within a CNS tumor is complicated by the presence of different barriers in the brain, including the blood–brain barrier (BBB), the blood-CSF barrier (BCSF) and the blood-tumor barrier (BTB). These barriers regulate the flow of ions, solutes, and nutrients into the brain, CSF, and tumor and generally prevent xenobiotics from gaining access. The physicochemical properties of some anticancer drugs prevent them from diffusing across these barriers and reaching the target tumor tissue, rendering them ineffective against CNS tumors (Oldendorf, 1974, de Lange, 2013). Often, preclinical studies do not take these barriers into account (e.g., cell culture studies, murine flank xenografts). Thus, it is not surprising that so many anticancer drugs fail once they are challenged with an intact brain/CNS barrier system.
Together, these challenges highlight the need for innovative approaches to develop new effective anticancer drugs for pediatric CNS tumors. The preclinical approach we discuss here uses tumor subgroup-specific preclinical models of pediatric CNS tumors, cerebral microdialysis sampling of tumor extracellular fluid (tECF), and pharmacokinetic modeling and simulation to overcome challenges that currently hinder progress in this field. While this approach does require a highly specialized team of researchers, the integration of pharmacologic principles into preclinical studies increases the likelihood of effectively translating preclinical findings to clinical trials of active drugs for CNS tumors.
Section snippets
Target drug exposure
Developing active anticancer drugs for patients with CNS diseases, including children with CNS tumors is daunting. In general, failure rates for oncology drugs are high, ca. 95% (Kola and Landis 2004). Specifically, failure rates for CNS drugs during Phase 2 and 3 studies are the highest of any therapeutic area, almost 2-fold higher than other indication (Kaitin and Milne, 2011, Bonate, 2013). To reduce the potential for clinical candidate attrition, our group has devised a preclinical
Lead compound selection
As noted earlier in the review, active anticancer drugs for children with CNS tumors are urgently needed. Thus, we describe in the following sections the process that was used to identify treatment leads for two very aggressive pediatric CNS tumor subtypes.
Results of recent high throughput screening (HTS) studies performed at our institution have identified multiple active drugs against two pediatric CNS tumors. The first, pemetrexed, a folate antagonist FDA-approved to treat pleural
Improving the development process for therapies to treat pediatric CNS tumors
Drug development for pediatric CNS tumors has historically followed the same paradigm as general pediatric oncology. An investigational or approved anticancer drug first shows promise in adult Phase 1–3 trials, typically for a variety of oncology indications. The anticancer drug is then tested against pediatric CNS tumors in vitro and in vivo, with the sophistication of these preclinical evaluations varying widely. Then, often with little information regarding the compound’s characteristics in
Future plans/summary
To date, our high-throughput screens, pharmacokinetic studies, and modeling and simulations thus far have focused on FDA approved compounds, however our next step is to evaluate non-FDA approved compounds and new chemical entities (NCEs) as potential anticancer drugs to treat CNS tumors in children. Since there will be little or no information available regarding formulation, systemic exposure, or tolerability for these agents, selecting an appropriate dosage for preclinical studies will be
Acknowledgements
The authors acknowledge the support of the Cancer Center Support CORE Grant P30 CA 21765 from the National Cancer Institute, The Collaborative Ependymoma Research Network (CERN), The V Foundation, and the American Lebanese Syrian Associated Charities. The authors thank the members of the St. Jude Brain Tumor Drug Development Leadership Group for their critical and helpful insights in the development of and the application of pharmacokinetic modeling and simulation to drug development for
References (38)
- et al.
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma
Cancer Cell
(2011) - et al.
Microdialysis-theory and application
Prog. Neurobiol.
(1990) - et al.
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
Lung Cancer
(2005) - et al.
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier
Brain Res. Brain Res. Rev.
(1997) - et al.
A simple model for the prediction of blood–brain partitioning
Int. J. Pharm.
(2000) - et al.
A mouse model of the most aggressive subgroup of human medulloblastoma
Cancer Cell
(2012) - et al.
Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF
J. Pharm. Sci.
(2004) - et al.
Snapshot PK: a rapid rodent in vivo preclinical screening approach
Drug Discovery Today
(2008) - et al.
Biologically targeted therapeutics in pediatric brain tumors
Pediatr. Neurol.
(2012) - et al.
Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors
J. Mol. Graph. Model.
(2010)